Medications

Antipsychotic reports positive results in Phase III trial

February 15, 2012     News release
news
Forest Laboratories and Gedeon Richter have announced preliminary top-line results from a Phase III clinical trial of Cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I disorder.

The missing link to "metabolic syndrome" -- FOUND!

February 2, 2012     Dennis Grantham, Editor-in-Chief
blog
For years, mental health providers have worried about the incidence of "metabolic syndrome" among consumers taking atypical antipsychotic meds for serious mental illness. Now, a study has identified the link.

A spending slowdown for psychiatric meds?

February 1, 2012     Nick Zubko, Associate Editor
blog
It’s hard to believe that psychiatric meds are anything but a “growth industry,” but that’s not really the case anymore, at least according to new research from Thomson Reuters and SAMHSA.

'Anatomy of An Epidemic' author writes back

December 6, 2011     Dennis Grantham, Editor-in-Chief
article
Robert Whitaker, author of Anatomy of an Epidemic, whose two-part interview in Behavioral Healthcare was the subject of critique by psychiatrist William Glazer MD (click here for Part I), issued a sharp and critical analysis of Glazer’s views in a Nov. 30 post at his own website.

Three key antipsychotics lose patent protection

November 16, 2011     Brian Albright
article
Pharmaceuticals are one of the fast growing cost centers in most state Medicaid programs, and antipsychotic medications are among the most expensive

Rebuttal: Questioning the Validity of ‘Anatomy of an Epidemic’ (Part II)

November 15, 2011     William M. Glazer, MD
article
Dr. Glazer argued that there are many plausible explanations for the observed rise in psychiatric disability in the past 20 years and that Whitaker's argument that psychiatric medications caused this trend is “speculative.” In this article, he addresses whether Whitaker's allegations also "endanger" the trust that doctors develop with their patients.

Rebuttal: Questioning the validity of 'Anatomy of an Epidemic'

October 30, 2011     William M. Glazer, MD
article
Psychiatrist says that claims of author Robert Whitaker's "Anatomy of an Epidemic" are sensational but scientifically unsound

A new antidepressant

October 4, 2011     William M. Glazer, MD
article
Vilazodone (Viibryd) introduces a new and unique mechanism of action

Transforming our thinking about psychiatric medications (Part II)

October 4, 2011     Lori Ashcraft, PhD and Bill Anthony, PhD
article
Part two of an exploration of author Robert Whitaker's controversial perspective on psychiatric medication, "Anatomy of an Epidemic."

Do most kids complete their antidepressant treatment?

August 24, 2011     News release
news
Columbus, Ohio – About half of Medicaid-covered children and adolescents in Ohio who are in treatment for depression complete their first three

Transforming our thinking about psychiatric medications

July 19, 2011     Lori Ashcraft, PhD and Bill Anthony, PhD
article
After interviewing Robert Whitaker, we found ourselves reminiscing about Toto in The Wizard of Oz. You remember, don't you? How Dorothy and her

The new wave of SGAs

July 19, 2011     William M. Glazer, MD
article
Page
of 4Next